DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Information source: Corcept Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: risperidone (Drug); risperidone matched placebo (Drug); risperidone-matched placebo (Drug); Mifepristone-matched placebo (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Corcept Therapeutics

Official(s) and/or principal investigator(s):
Coleman Gross, MD, Study Director, Affiliation: Corcept Therapeutics

Summary

This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in absolute weight at Day 28 compared to baseline.

Clinical Details

Official title: A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Primary outcome: Change in Weight (kg) From Baseline to Day 28.

Secondary outcome:

The Secondary Study Objectives Are to Determine the Mean Percent Change in Baseline Body Weight; and the Proportion of Subjects That Gain Less Than 5% and Less Than 7% of Their Baseline Body Weight in the Treatment Groups.

The Safety Objective is to Evaluate the Safety and Tolerability of Mifepristone in Combination With Risperidone in Healthy Male Volunteers.

Detailed description: This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers. The primary study objective is to determine the mean change in absolute weight at Day 28 compared to baseline in normal healthy male volunteers treated with risperidone plus mifepristone or risperidone alone. The secondary study objectives are to determine the mean percent change in baseline body weight; and the proportion of subjects that gain less than 5% and less than 7% of their baseline body in the treatment groups.

Eligibility

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- BMI ≥ 18 and ≤ 23 kg/m2

- Able to provide written informed consent

- Routine clinical laboratory tests either within normal limits or not clinically

meaningful if outside of normal limits

- AST, ALT, Tbili within normal limits at screening

- Medical and psychiatric history and physical examination devoid of any significant

findings that would interfere with participation or interpretation of results in this study

- Agree to use a barrier method of birth control for 28 days following the last dose of

study medication

- Have maintained a stable weight for at least 6 months prior to Screening

Exclusion Criteria:

- Prior or current history of any psychiatric disorder, including eating disorders such

as anorexia nervosa, bulimia nervosa, or binge-eating disorder

- Positive urine drug screen for any drug of abuse (including amphetamines,

cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) unless prescribed by a physician

- Participation in a clinical investigation of any drug, biological or other

investigational therapy within 30 days prior to dosing

- Have a history of an allergic reaction to either mifepristone or risperidone

- Any other clinically significant abnormality on screening laboratory tests

- QTc Bazzett's ≥ 450 msec

- History of or current major medical condition, which in the opinion of the

Investigator would place the patient at undue risk.

- Receiving any prescription or over-the-counter medications that could potentially

affect appetite or weight

- Any history of a movement disorder such as Tardive Dyskinesia, Parkinsonism

- Any personal or family history of Neuroleptic Malignant Syndrome

Locations and Contacts

Dhirubhai Ambani Life Sciences Centre, Mumbai, India
Additional Information

Sponsor's Website

Related publications:

Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.

Starting date: November 2008
Last updated: May 1, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017